期刊文献+

血清S-CD105在结直肠癌中的表达及临床意义 被引量:2

Expression and Clinical Significance of Serous S-CD105 in Colorectal Cancer
下载PDF
导出
摘要 目的探讨血清S-CD105在结直肠癌中的表达及临床意义。方法选择北京军区天津疗养院收治的经病理证实的结直肠癌35例(结直肠癌组)、结直肠息肉10例(结直肠息肉组)和健康体检者10例(对照组),用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测血清S-CD105的浓度,观察其与临床病理指标的关系及预后。结果结直肠癌组术前S-CD105浓度均高于术后及结直肠息肉组、对照组(P〈0.05);结直肠息肉组和对照组比较差异无统计学意义(P〉0.05);结直肠癌组术后S-CD105浓度均低于结直肠息肉组和对照组,但差异无统计学意义(P〉0.05)。血清S-CD105浓度随着淋巴结转移、Dukes分期升高及癌组织中血管内皮生长因子(VEGF)表达增强而明显升高(P〈0.05);术后1~3年发生远处转移的5例结直肠癌血清S-CD105浓度明显升高。结论血清SCD105表达对评价结直肠癌的预后和监测复发、转移具有重要的临床价值。 Objective To explore the expression and clinical significance of serous S-CD105 in colorectal cancer. Methods Concentrations of serous S-CD105 in 35 patients with colorectal cancer confirmed by pathology( group A),10 patients with colorectal polyp( group B) and 10 persons by health examinations( control group) in our hospital were detected by using enzyme-linked immunosorbent assay( ELISA),and the relationships between concentrations with clinical factors and prognosis were also observed. Results The preoperative concentration of serous S-CD105 in group A was significantly higher than those in group A after operation,group B and control group( P < 0. 01,P < 0. 05); the difference between group B and control group was not statistically significant( P > 0. 05); the postoperative concentration of serous S-CD105 in group A was lower than those of group B and control group,but the differences were not statistically significant( P > 0. 05). The concentration of serous S-CD105 obviously was elevated with the lymph node metastasis,the later stage of Dukes and the enhanced expression of vascular endothelial growth factor( VEGF) in the cancer tissue( P < 0. 05); concentrations of serous S-CD105 obviously raised in 5 patients with colorectal cancer and with distant metastasis postoperative 1-3 years. Conclusion The expression of serous S-CD105 in colorectal cancer has important clinical significance in evaluating the prognosis,monitoring recurrence and metastasis of colorectal cancer.
出处 《解放军医药杂志》 CAS 2013年第12期72-74,共3页 Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
关键词 结直肠肿瘤 S-CD105 酶联免疫吸附测定 预后 Colorectal neoplasm S-CD105 Enzyme-linked immunosorbent assay Prognosis
  • 相关文献

参考文献7

二级参考文献195

  • 1张艺,姜秀文,赵素琴,叶黎霞.芦荟治疗异长春花碱外渗致局部损伤的效果观察[J].上海护理,2006,6(5):39-40. 被引量:5
  • 2胡华莉,王文娟,施妙春.芦荟外敷预防静脉输注诺维本致静脉损伤的效果观察[J].护理研究(上旬版),2006,20(12):3159-3160. 被引量:7
  • 3Devereux RB, Lyle PA. Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan intervention for endpoint reduction in hypertension (LIFE) study. Expert Opin Pharmacother 2004; 5:2311-2320.
  • 4Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke "fetal" contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85:507-514.
  • 5Rosenkranz S, Flesch M, Amann K, et al. Alterations of β- adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1. Am J Physiol Heart Circ Physiol2002; 283:H1253-1262.
  • 6Goumans M J, Zonneveld A J, ten Dijke E TGFβ-induced endothelial to mesenchymal transition; a switch to cardiac fibrosis? Trends Cardiovase Med, in press.
  • 7Larsson J, Goumans M J, Sjostrand L J, et al. Abnormal angiogenesis but intact hematopoietic potential in TGF-β type Ⅰ receptor-deficient mice. EMBO J 2001; 20:1663-1673.
  • 8Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333:918-924.
  • 9Heldin C-H, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390:465-471.
  • 10Shi Y, Massague J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113:685-700.

共引文献52

同被引文献39

  • 1伍冀湘,梁杰雄,王宇夫,李雅君,温绍君,李进军,邵天松,邱力新,何平,魏常胜,贺建业,曹广,胡海鸥,钟山,侯迎晨,周京安.腹腔镜和开腹结直肠癌根治手术患者外周血中CK20mRNA的表达及意义[J].首都医科大学学报,2007,28(1):10-13. 被引量:4
  • 2Hurria A, Lachs M S, Cohen H J, et al. Geriatric assess- ment for oncologists : rationale and future directions [ J ]. Crit Rev Oncol Hematol, 2006,59 ( 3 ) :211-217.
  • 3Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage I1 or III colon cancer in the MOSAIC trial [ J ]. J Clin Oncol, 2009,27 ( 19 ) : 3109- 3116.
  • 4Zuckerman I H, Davidoff J, Onulwagha E,et al. Effect of age on survival benefit of adjuvant chemotherapy in elder- ly stage m colon cancer patients:a population-based anal- ysis[ J]. J Clin Oncol, 2008,26(15S) :4014.
  • 5Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008,58(2) :71-96.
  • 6Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials [ J]. J Clin Oncol, 2009,27 (6) : 872 -877.
  • 7ZangD Y, Lee B H, Park H C, et al. Phase II study with oxaliplatin and S-1 for patients with metastatic color- ectal cancer[ J ]. Ann Oncol, 2010,20 ( 5 ) : 892-896.
  • 8Tan K Y, Konishi F, Suzuki K. The evidence for adju- vant treatment of elderly patients ( age > or = 70) with stage III colon cancer is inconclusive [ J ]. Surg Today, 2010,40(4) :385-387.
  • 9McCleary N J, Meyerhardt J A, Green E, et al. Impact of age on the efficacy of newer adjuvant therapies in pa- tients with stage II/III colon cancer: findings from the ACCENT database [ JJ. J Clin Oncol, 2013,31 (20) : 2600 -2606.
  • 10Cassidy J, Clarke S, Diaz Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[ J] J Clin Oncol, 2008,26( 12 ) :2006-2012.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部